Targets › CGB
2 programs from 2 companies in 2 trials: 1 Phase 3, 1 Phase 4; Genitourinary; next expected readout Dec 2027.
Open in Phaseline: the race on CGB, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Fertility Center of Las Vegas | hCG injection human chorionic gonadotropin - luteal phase support | CGA, CGB | Phase 4 | Infertility (IVF Patients) | Dec 2027 |
| Kristine Loessl | Choriongonadotropin alfa Human chorionic gonadotropin (hCG) agonist | CGA, CGB | Phase 3 | Infertility, Female | Mar 2028 |
Infertility, Female (1) Infertility (IVF Patients) (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.